Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 2/20 | 1.00 |
| ▸ | EPHB2 | P29323 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 6/20 | 0.81 |
| ▸ | RET | P07949 | 3/20 | 0.81 |
| ▸ | LCK | P06239 | 5/20 | 0.79 |
| ▸ | SRC | P12931 | 1/20 | 0.70 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.69 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.69 |
| ▸ | FLT1 | P17948 | 1/20 | 0.69 |
| ▸ | GAK | O14976 | 1/20 | 0.69 |
| ▸ | STK10 | O94804 | 1/20 | 0.69 |
| ▸ | FLT3 | P36888 | 1/20 | 0.69 |
| ▸ | JAK3 | P52333 | 1/20 | 0.69 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.69 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.69 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.69 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.69 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.69 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1387206 | 1.00 | EGFR (1.00) | EGFRRIPK2EPHB2KDRRET | |
| Hydrochloric Acid SCHEMBL8807925 | 0.99 | EGFR (0.98) | EGFRRIPK2EPHB2KDRRET | |
| SCHEMBL21442463 | 0.92 | EGFR (0.84) | EGFRRIPK2EPHB2KDRRET | |
| SCHEMBL15390777 | 0.91 | EGFR (0.83) | EGFRRIPK2EPHB2KDRRET | |
| SCHEMBL18158215 | 0.90 | EGFR (0.82) | EGFRRIPK2EPHB2KDRRET | |
| SCHEMBL1387182 | 0.90 | EGFR (0.94) | EGFRRIPK2EPHB2KDRRET | |
| SCHEMBL29515328 | 0.90 | EGFR (1.00) | EGFRRIPK2EPHB2KDRRET | |
| SCHEMBL1257431 | 0.90 | EGFR (1.00) | EGFRRIPK2EPHB2KDRRET | |
| Hydrochloric Acid SCHEMBL8811926 | 0.89 | EGFR (0.80) | EGFRRIPK2EPHB2KDRRET | |
| SCHEMBL8933814 | 0.89 | KDR (0.88) | EGFRRIPK2EPHB2KDRRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119854122-A | Dynamic optimization system and method for monitoring strategy of voice video local area network | 华能龙开口水电有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-119696759-A | Editable medical block chain system with privacy protection function | 福建师范大学 | 2025-03-25 | — | — | CN | claimed |
| CN-118509262-B | Lightweight forward-backward secure public key authentication encryption keyword searching method and system | 青岛大学 | 2024-11-15 | — | — | CN | claimed |
| CN-118917390-A | Knowledge base management system and method based on knowledge big model | 中国标准化研究院 | 2024-11-08 | — | — | CN | claimed |
| CN-118573399-A | Concealed communication method based on bit coin payment system | 中国人民武装警察部队工程大学 | 2024-08-30 | — | — | CN | claimed |
| CN-116886311-B | Policy signature method, system and storage medium based on blockchain privacy security | 三未信安科技股份有限公司 | 2024-08-16 | — | — | CN | claimed |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | claimed |
| CN-114677218-A | Off-link transaction method based on payment knot | 南京邮电大学 | 2022-06-28 | — | — | CN | claimed |
| CN-113422685-B | Certificateless searchable public key encryption method and system for time-limited revocation of search token | 南京师范大学 | 2022-06-24 | — | — | CN | claimed |
| US-20260146252-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| CN-122024473-A | Road right management and control method, device, storage medium and program product | 浙江吉利控股集团有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260085107-A1 | PRODUCTION OF PROTEINS, INCLUDING SECRETED PROTEINS | GINKGO BIOWORKS, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4711459-A2 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | Ionis Pharmaceuticals, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260048133-A1 | METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2026-02-19 | — | — | US | disclosed |
| US-20220098663-A1 | BIOMARKERS FOR CONGENITAL VASCULAR MALFORMATIONS | UNIVERSITY OF SOUTH CAROLINA (US) | 2022-03-31 | — | — | US | disclosed |
| US-20220089696-A1 | ARENAVIRUS MONOCLONAL ANTIBODIES AND USES | ZALGEN LABS, LLC | 2022-03-24 | — | — | US | disclosed |
| US-20220062404-A1 | GP38-TARGETING MONOCLONAL ANTIBODIES PROTECT ADULT MICE AGAINST LETHAL CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS INFECTION | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2022-03-03 | — | — | US | disclosed |
| US-11260133-B2 | Methods and compositions related to peptides and proteins with C-terminal elements | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2022-03-01 | — | — | US | disclosed |
| CN-114058617-A | Conjugated antisense compounds and uses thereof | IONIS制药公司 | 2022-02-18 | — | — | CN | disclosed |
| US-20220049017-A1 | ANTAGONISTS | KYMAB LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146252-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | SI, FABP2, FUT6 | EGFR 2386/4885RIPK2 4605/4885EPHB2 1965/4885 |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | EGFR 1887/4885RIPK2 3348/4885EPHB2 336/4885 |
| US-11260133-B2 | Methods and compositions related to peptides and proteins with C-terminal elements | CD2BP2, CLTC, CLTA | EGFR 234/4885RIPK2 2858/4885EPHB2 1451/4885 |
| US-20260048133-A1 | METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | CMKLR2, CRKL, CMKLR1 | EGFR 14/4885RIPK2 1031/4885EPHB2 1341/4885 |
| US-20260085107-A1 | PRODUCTION OF PROTEINS, INCLUDING SECRETED PROTEINS | HSPA5, UPF1, PDIA6 | EGFR 3853/4885RIPK2 4602/4885EPHB2 3842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.